RIPGBM

Cat. No.:	HY-122910
CAS No.:	355406-76-7
Molecular Formula:	$C_{26}H_{21}FN_2O_3$
Molecular Weight:	428.45
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (77.79 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3340 mL	11.6700 mL	23.3399 mL
	5 mM	0.4668 mL	2.3340 mL	4.6680 mL
	10 mM	0.2334 mL	1.1670 mL	2.3340 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC_{50} of ≤500 nM[1].

IC_{50} & Target

EC50: ≤500 nM (Apoptosis, in GBM CSCs)[1]

In Vitro

RIPGBM induces caspase 1-dependent apoptosis by binding to receptor-interacting protein kinase 2 (RIPK2) and acting as a molecular switch, which reduces the formation of a prosurvival RIPK2/ TAK1 complex and increases the formation of a proapoptotic RIPK2/caspase 1 complex[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Lucki NC, et al. A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancer. Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6435-6440.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA